Joyzyme Group Limited

Joyzyme Group Limited

HHKEX:8622
0.29
HKD
+0.00
(-1.69%)
49.01MMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.05
0.06
0.07
0.09
0.06
0.05
0.07
0.06
0.06
0.05
0.06
- -
Basic EPS, GAAP
0.02
0.02
- -
- -
- -
-0.03
-0.01
-0.01
-0.01
-0.01
-0.01
- -
Free Cash Flow per Basic Share
- -
0.02
-0.01
-0.01
-0.01
-0.02
-0.01
- -
- -
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
0.06
0.09
0.18
0.18
0.15
0.14
0.14
0.12
0.11
0.1
0.11
Tangible Book Value per Share
0.04
0.06
0.09
0.17
0.17
0.15
0.14
0.13
0.12
0.11
0.1
0.11
Basic Weighted Avg Shares
400
400
400
305
400
400
400
405
416
482
501
428
Sales/Revenue/Turnover
19
25
27
29
25
22
26
25
25
25
28
- -
Operating Margin (%)
47.64
44.09
-2.34
9.18
0.07
-47.4
-14.47
-17.21
-26.32
-19.34
-27.61
- -
Depreciation Expense
1
1
1
2
3
3
3
3
3
3
4
- -
Net Income, GAAP
8
8
-2
- -
- -
-12
-4
-3
-6
-4
-5
- -
Effective Tax Rate (%)
13.79
15.27
- -
136.96
143.16
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
40.78
33.16
-7.35
-1.6
-1.11
-52.93
-16.15
-12.14
-23.48
-16.4
-17.7
- -
Working Capital
9
17
25
58
56
50
45
44
40
44
43
47
LT Debt
1
- -
- -
- -
- -
1
1
- -
1
- -
1
1
Total Equity
16
24
37
71
71
62
58
57
51
54
51
56
Return on Invested Capital (%)
- -
38.1
- -
-0.86
-0.02
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
40.16
- -
-0.85
-0.44
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
42.16
-6.34
-0.85
-0.4
-17.54
-7.06
-5.38
-10.75
-7.91
-9.52
- -

Capital Structure

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
416
418
500
Market Capitalization
49
41
46

Working Capital

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
53
56
Cash, Cash Equivalents & STI
- -
33
37
Accounts Receivable, Net
- -
15
15
Inventories
- -
3
3
Total Current Liabilities
- -
13
10
Payables & Accruals
- -
- -
- -
ST Debt
- -
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.7%
-3.58%
-5.35%
Free Cash Flow
35.84%
-70.98%
-22.9%
Net Income, GAAP
375.19%
-2.1%
20.39%
Sales/Revenue/Turnover
4.58%
5.52%
11.53%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
25
2025
- -
- -
28
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Lai Yin Poon
Full Time Employees
101
Sector
Health technology
Industry
Medical specialties
Address
Chinachem Golden Plaza Hong Kong Hong Kong
IPO Date
Dec 13, 2018
Business
Huakang Biomedical Holdings Company Limited, an investment holding company incorporated in the Cayman Islands in 1992 and headquartered in Tsim Sha Tsui, Hong Kong, with principal operations in the People's Republic of China, engages in the research, development, production, marketing and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment; as well as healthcare products and supplements. The company offers a portfolio of 31 biological reagents, including 28 male fertility in-vitro diagnostic reagents, two parasite antibody detection reagents and one Epstein-Barr virus antibody detection reagent; auxiliary reproductive supplies and equipment such as semen biochemical immunoassay equipment; and healthcare supplements previously marketed under the Nutronic brand. It sells products directly to hospitals and medical institutions, as well as through distributors, primarily serving the healthcare sector in the PRC with a focus on male infertility diagnostics and assisted reproductive technologies. In April 2025, an indirect wholly-owned subsidiary entered into an equity transfer agreement to acquire 91% of Hunan Keyue Biotechnology Co., Ltd., a PRC-based entity specializing in women's health products including female reproductive solutions, health foods and antibacterial items under the Yukunshu and Qinghuiyue brands, for RMB317,697, marking a strategic expansion into the women's health market; the company also completed placings of 82 million shares in early 2024 raising approximately HK$8 million and registered its semen biochemical immunoassay equipment as a Class II medical device in late 2024, while suspending Nutronic sales amid market challenges.